Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.
Impact
The bill introduces specific limitations that will require entities involved in pharmacy operations to comply within a set timeframe. Notably, it mandates that individuals or organizations found in violation of these provisions must divest their interests in any conflicting pharmacies or insurance companies within three years of the bill's enactment. The legislation empowers the attorney general to enforce these rules and impose hefty penalties for non-compliance, which could amount to $10,000 per day for entities that do not adhere to the new regulations.
Summary
Bill A09184 aims to restrict overlapping control between insurance companies, pharmacy benefit managers, and pharmacies. The legislation proposes to make it unlawful for any person or entity to own or operate a pharmacy if they also control an insurance company or pharmacy benefit manager, or any combination thereof. This measure addresses concerns about potential conflicts of interest and aims to ensure that pharmacies operate independently of any influence from companies that manage health plans or insurance, thus promoting consumer protection and transparency in the pharmaceutical market.
Contention
While supporters of A09184 argue that the bill is a necessary step to curb unethical practices in the insurance and pharmaceutical sectors, some skeptics raise concerns about its potential impact on operational efficiencies. Critics may argue that such divestment requirements could hinder business models that rely on integrated healthcare services. These opponents may be particularly concerned that this separation could lead to increased costs for consumers and limit the availability of comprehensive care solutions, as the streamlining of services offered by connected operations could be disrupted.
Same As
Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.
Provides limitations on overlapping control between insurance companies and pharmacy benefits managers and pharmacies; requires divestment of the interest in one or more insurance companies and pharmacy benefits managers.